It’s not all doom and gloom for struggling Singapore small-caps

Smaller players can still outperform the market.

Although Singapore stocks were hammered in the first two trading weeks of 2016, analysts at DBS Vickers are still convinced that a few select small-capitalisation companies can manage to outperform the market this year.

DBS' small-cap strategy hinges on three themes: growth, prospective yield, and recovery. DBS favours stocks which have clear drivers and catalysts, such foolproof expansion plans, potential forex gains, anticipated price rebounds and attractive dividend yields.

“Small-cap names can often shine despite uncertainty and malaise in the broader market,” DBS said.

DBS’ conviction picks are film production company mm2 Asia, glove maker Riverstone Holdings, agribusiness player Japfa, grocery operator Sheng Siong, and conglomerate China Merchants Holdings.
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare